- Home
- ARQT vs BBT Comparison
ARQT vs BBT Comparison
Compare ARQT & BBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- BBT
- Stock Information
- Founded
- ARQT 2016
- BBT 1846
- Country
- ARQT United States
- BBT United States
- Employees
- ARQT N/A
- BBT N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- BBT Banks
- Sector
- ARQT Health Care
- BBT Finance
- Exchange
- ARQT Nasdaq
- BBT Nasdaq
- Market Cap
- ARQT 2.1B
- BBT 2.2B
- IPO Year
- ARQT 2020
- BBT N/A
- Fundamental
- Price
- ARQT $16.93
- BBT N/A
- Analyst Decision
- ARQT Strong Buy
- BBT Hold
- Analyst Count
- ARQT 7
- BBT 1
- Target Price
- ARQT $19.00
- BBT $33.00
- AVG Volume (30 Days)
- ARQT 1.5M
- BBT 537.9K
- Earning Date
- ARQT 11-05-2025
- BBT 11-08-2025
- Dividend Yield
- ARQT N/A
- BBT 5.04%
- EPS Growth
- ARQT N/A
- BBT 2.47
- EPS
- ARQT N/A
- BBT 2.10
- Revenue
- ARQT $263,464,999.00
- BBT $345,393,000.00
- Revenue This Year
- ARQT $72.46
- BBT $47.36
- Revenue Next Year
- ARQT $32.00
- BBT $79.15
- P/E Ratio
- ARQT N/A
- BBT $12.18
- Revenue Growth
- ARQT 99.50
- BBT 2.90
- 52 Week Low
- ARQT $8.03
- BBT $22.27
- 52 Week High
- ARQT $18.15
- BBT $32.36
- Technical
- Relative Strength Index (RSI)
- ARQT 57.20
- BBT N/A
- Support Level
- ARQT $15.13
- BBT N/A
- Resistance Level
- ARQT $18.15
- BBT N/A
- Average True Range (ATR)
- ARQT 0.67
- BBT 0.00
- MACD
- ARQT 0.08
- BBT 0.00
- Stochastic Oscillator
- ARQT 60.00
- BBT 0.00
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.